Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An announcement from TMS Co., Ltd. ( (JP:4891) ) is now available.
TMS Co., Ltd. announced that CEO Takuro Wakabayashi and board member Reiko Namikawa will host an executive roundtable at the WuXi Global Forum 2025 in San Francisco, focusing on acute-phase therapeutics. This participation underscores TMS’s commitment to addressing overlooked medical needs and enhances its visibility in the biopharmaceutical industry, potentially expanding its influence and collaborations in the global market.
More about TMS Co., Ltd.
TMS Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to developing transformative medicines for serious diseases with high unmet medical needs. Their pipeline features small molecule compounds called SMTPs, with a lead program, TMS-007, showing promise in treating acute ischemic stroke. The company also explores treatments for resistant hypertension, acute kidney injury, and spinal cord injury, leveraging partnerships with Japanese academic institutions.
YTD Price Performance: 0%
Average Trading Volume: 546,554
Technical Sentiment Consensus Rating: Hold
Current Market Cap: Yen8.79B
Learn more about 4891 stock on TipRanks’ Stock Analysis page.